In vitro characterization of baloxavir acid, a first‐in‐class cap‐dependent endonuclease inhibitor of the influenza virus polymerase PA subunit
Sign Up to like & getrecommendations! Published in 2018 at "Antiviral Research"
DOI: 10.1016/j.antiviral.2018.10.008
Abstract: ABSTRACT Cap‐dependent endonuclease (CEN) resides in the PA subunit of the influenza virus and mediates the critical “cap‐snatching” step of viral RNA transcription, which is considered to be a promising anti‐influenza target. Here, we describe… read more here.
Keywords: bxa; inhibitor; baloxavir acid; vitro characterization ... See more keywords
Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission
Sign Up to like & getrecommendations! Published in 2022 at "PLoS Pathogens"
DOI: 10.1371/journal.ppat.1010698
Abstract: Baloxavir marboxil (BXM) is approved for treating uncomplicated influenza. The active metabolite baloxavir acid (BXA) inhibits cap-dependent endonuclease activity of the influenza virus polymerase acidic protein (PA), which is necessary for viral transcription. Treatment-emergent E23G… read more here.
Keywords: e23g substitutions; transmission; influenza virus; bxa ... See more keywords